FOLH1 and cancer: As a radioligand therapeutic agent, lutetium (177Lu) vipivotide tetraxetan consists of a radionuclide, lutetium Lu-177, conjugated to a prostate-specific membrane antigen (PSMA)-binding moiety, exercising cytotoxic effect on cancer cells [138, 139].